Despite a negative trial of oral Ozempic in mild Alzheimers, the rationale for GLP-1 drugs in neurodegenerative disease remains strong
Therapeutic innovation now includes dual and triple incretin receptor agonists [4,5,6,7] as well as orally bioavailable small-molecule formulations [8, 9], reflecting ongoing efforts to enhance pharmacodynamic durability
Although we do not prescribe CJC 1295, we believe in helping our patients understand how peptides in this category work and how medically supervised alternatives such as Tesamorelin can safely support similar outcomes
Talk to your provider about the right timing for you
Without FDA oversight of the compounding process, potency consistency is less guaranteed than with brand-name products
Blood Sugar Regulation : GLP-1 helps the body release insulin when blood sugar rises, which can help stabilize blood sugar levels, especially for those with insulin resistance